30-06-2025
Biocon Surpasses 100 Million Insulin Cartridges Supplied To MOH
Biocon Biologics Ltd's Malaysian arm, Biocon Sdn Bhd has crossed a major milestone by supplying over 100 million cartridges of recombinant human insulin (rh-insulin) to Malaysia's Ministry of Health since 2016, benefitting more than 345,000 diabetes patients nationwide.
The insulin is produced at Biocon's state-of-the-art manufacturing facility in Johor, established with a cumulative investment of US$600 million. Recognised by the Malaysia Book of Records as the first and largest integrated insulin manufacturer in the country, the plant produces a wide range of insulins in various delivery forms.
'Every cartridge we produce at our state-of-the-art facility in Johor is a lifeline for someone living with diabetes,' said Biocon Biologics Chief Commercial Officer Susheel Umesh.
Biocon Biologics' longstanding partnership with the Ministry of Health and Duopharma Marketing Sdn. Bhd. aims to advance insulin access and healthcare resilience. Leonard Ariff Abdul Shatar, Group Managing Director of Duopharma Biotech Berhad, reaffirmed this, stating the collaboration is focused on delivering affordable, high-quality insulin to Malaysians.
Globally, Biocon Biologics is ranked among the top three producers of rh-insulin and Insulin Glargine, having delivered 9.2 billion doses to date. Related
